![](https://www.pymnts.com/wp-content/uploads/2023/07/FTC-6.jpg)
Pfizer’s proposed $43 billion takeover of Seagen Inc. is currently under the microscope of the Federal Trade Commission (FTC). Amidst an industry-wide string of attempted mergers and acquisitions, the FTC has launched an extensive antitrust review of the high-profile deal.
Seagen claimed that both companies have been served a “second request” seeking additional information to fuel the review. Originally, the filing was withdrawn in June, but Pfizer and Seagen then resubmitted it to grant the FTC more time to conduct their initial evaluation.
“We continue to expect that the acquisition of Seagen by Pfizer will be completed in late 2023 or early 2024,” said Seagen in a regulatory filing, reported Reuters.
Yet even this optimistic prediction has been clouded by the scrutiny of the FTC blocking Amgen’s attempted purchase of Horizon Therapeutics for $27.8 billion, leaving investors on edge.
Read more: French Government Criticizes Appointment Of US Economist As Chief Antitrust Advisor
Commenting on the acquisition, Alicia Dubuc of the FTC said: “We recognize the need to examine with particular scrutiny proposed mergers that may result in lessening of competition and higher prices for consumers. We remain diligent in protecting the American public from these potential harms.”
The Pfizer-Seagen deal is being viewed as an indicator of the Federal Trade Commision’s attitude towards mergers and acquisitions amongst biopharmaceutical firms. As investors anxiously await the results of the review, it will likely set a long-term trend across the industry.
Source: Reuters
Featured News
Nvidia and Microsoft Sued for Allegedly Undercutting AI Technology Patent Prices
Sep 5, 2024 by
CPI
White & Case Strengthens Antitrust and M&A Practices with New Partner Additions
Sep 5, 2024 by
CPI
Federal Judge Dismisses Antitrust Lawyers’ Fee Demand Over JetBlue-Spirit Deal
Sep 5, 2024 by
CPI
Boston Landlords Named as US Sues RealPage Over Alleged Rent-Inflating Practices
Sep 5, 2024 by
CPI
Judge to Weigh Landmark NCAA Settlement Proposal in Antitrust Lawsuit
Sep 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI